PMID- 35379123
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221024
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 23
IP  - 15
DP  - 2022
TI  - Gut Microbiota Might Act as a Potential Therapeutic Pathway in COVID-19.
PG  - 1837-1850
LID - 10.2174/1389201023666220404183859 [doi]
AB  - It has been very recently suggested that individuals with chronic gut 
      inflammation are highly susceptible to COVID-19. They constitute the serious 
      cases of COVID-19, in which inflammatory cytokine storm is observed. On the 
      contrary, the healthy gut microbiota is linked with low chronic gut and systemic 
      inflammation. This raises the idea that maintenance of the healthy gut microbiota 
      and prevention of gut microbial dysbiosis in COVID-19 patients might avoid the 
      increased cytokine storm, which in turn might reduce the mortality rate. It has 
      been shown that the modulation of the gut microbiota is an effective strategy to 
      strengthen immunity and might be a possible treatment for individuals with viral 
      infections. Currently, there is no clinical data considering the impact of the 
      modulation of the gut microbiota on the treatment of COVID-19. We hypothesize 
      that targeting the gut microbiota might be a novel therapeutic approach or at 
      least a supportive therapy. In the present review article, we described the 
      interaction between SARS-CoV-2 and gut microbiota dysbiosis through two possible 
      mechanisms, including aberrant immune activation and aberrant mammalian target of 
      rapamycin (mTOR) activation. Further, the disruption of the gastrointestinal 
      reninangiotensin system (GI RAS), dysregulation of the coagulation and 
      fibrinolytic systems, and the activity of human serine proteases in COVID-19 
      pathogenesis were addressed. We also provided possible strategies to restore all 
      the discussed aspects via gut microbiota modulation.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Gharajeh, Nahid Hosseinzadeh
AU  - Gharajeh NH
AD  - Department of Plant Breeding and Biotechnology, Faculty of Agriculture, 
      University of Tabriz, Tabriz, Iran.
FAU - Pourjafar, Hadi
AU  - Pourjafar H
AD  - Dietary Supplements & Probiotic Research Center, Alborz University of Medical 
      Sciences, Karaj, Iran.
FAU - Derakhshanian, Hoda
AU  - Derakhshanian H
AD  - Dietary Supplements & Probiotic Research Center, Alborz University of Medical 
      Sciences, Karaj, Iran.
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mohammadi, Hamed
AU  - Mohammadi H
AD  - Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, 
      Karaj, Iran.
AD  - Department of Immunology, School of Medicine, Alborz University of Medical 
      Sciences, Karaj, Iran.
FAU - Barzegari, Abolfazl
AU  - Barzegari A
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Eslami, Solat
AU  - Eslami S
AD  - Dietary Supplements & Probiotic Research Center, Alborz University of Medical 
      Sciences, Karaj, Iran.
AD  - Department of Medical Biotechnology, School of Medicine, Alborz University of 
      Medical Sciences, Karaj, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.4.- (Serine Proteases)
SB  - IM
MH  - Humans
MH  - *COVID-19
MH  - *Gastrointestinal Microbiome
MH  - Dysbiosis
MH  - SARS-CoV-2
MH  - Cytokine Release Syndrome
MH  - Inflammation
MH  - TOR Serine-Threonine Kinases
MH  - Serine Proteases
OTO - NOTNLM
OT  - COVID-19
OT  - Gut microbiota modulation
OT  - dysbiosis
OT  - gut inflammation
OT  - renin-angiotensin system
OT  - viral infection
EDAT- 2022/04/06 06:00
MHDA- 2022/10/25 06:00
CRDT- 2022/04/05 05:26
PHST- 2021/11/01 00:00 [received]
PHST- 2022/01/20 00:00 [revised]
PHST- 2022/02/01 00:00 [accepted]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/04/05 05:26 [entrez]
AID - CPB-EPUB-122262 [pii]
AID - 10.2174/1389201023666220404183859 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2022;23(15):1837-1850. doi: 
      10.2174/1389201023666220404183859.